Fexagratinib targets FGF, CSF, and VEGF pathways, showing potential in MS treatment by reducing inflammation and promoting ...

The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...

The complex relationship between possibly impaired cognitive function in patients with multiple sclerosis (MS) and fasting ...

A total of 7 states passed ballot measures during the 2024 presidential election to enshrine abortion access into their state ...

Inteleclinic AI tool automates neuromuscular exam scoring, reducing time and ensuring consistent assessments across settings.

A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non ...

The study evaluated a reduced-intensity conditioning regimen without total body irradiation for alloHCT in DC/TBD patients.

The Quadruple Aim—a framework originally rooted in improving patient experience, enhancing population health, and achieving ...

RILD in NHL patients presents as lung disease, organizing pneumonia, and nonspecific interstitial pneumonia, with 179 ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

A new study aimed to explore the role of stress hyperglycemia ratio (SHR) in predicting mortality risks for patients with ...